- Integra LifeSciences Holdings Corp IART reported Q3 FY22 sales of $385.19 million, -0.4% Y/Y on a reported basis, and +3.5% organic, beating the consensus of $381.24 million.
- Adjusted EPS stood at $0.86, ahead of the Street estimate of $0.73.
- Adjusted gross margin was 66.7%, compared to 68.3% in the prior year.
- Adjusted EBITDA was $105.3 million, or 27.3% of revenue, compared to $104.3 million, or 27.0% of revenue, in the prior year.
- The company completed the sale of its non-core traditional wound care business at the end of August 2022.
- Guidance: For FY22, Integra Lifescience sees revenue of $1.551-$1.563 billion (prior view $1.548-$1.566 billion).
- The guidance considers the macro environment, continuing supply constraints, and potential adjustments to the CereLink reserve.
- The company raised FY22 adjusted EPS to $3.29-$3.33 vs. the earlier outlook of $3.12-$3.20 and the consensus of $3.15.
- For Q4, IART expects sales of $391-$403 million vs. the consensus of $403.5 million. It sees adjusted EPS of $0.87-$0.91 (consensus of $0.88).
- Price Action: IART shares are up 5.43% at $47.02 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in